204 results
Page 5 of 11
8-K
EX-99.1
rpb9303p
22 Jan 20
ImmunoGen Announces Proposed Public Offering of Common Stock
4:09pm
424B5
r4xbj cqje
22 Jan 20
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
ig32thlld3wde1
17 Dec 19
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
kdn5d
1 Nov 19
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
6:54am
8-K
EX-99.1
4q2fjdkk
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K
EX-99.2
vpxoyppphp
30 Sep 19
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
8:08am
8-K/A
EX-99.1
5mme1ktae
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
10:33am
8-K
EX-99.1
2s5dh
2 Aug 19
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
6:38am
8-K
EX-99.1
3q88aj0oxc5
27 Jun 19
ImmunoGen Announces Completion of Operational Review
6:35am
8-K
EX-99.1
uxg gcvci1
3 May 19
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
6:36am
8-K
EX-99.1
0a55y28s b5naf
8 Feb 19
ImmunoGen Reports Recent Progress and 2018 Operating Results
6:37am
8-K
EX-99.1
oogdw wxxuzer2gf5r6n
26 Nov 18
ImmunoGen Announces Resignation of Chief Financial Officer
4:15pm
8-K
EX-99.1
r6zio9724kj
2 Nov 18
ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
6:36am